Advanced search
Publication Cover
OncoImmunology Volume 6, 2017 - Issue 12
Submit an article Journal homepage
2,401
Views
40
CrossRef citations to date
0
Altmetric
Original Research

CAR T-cell immunotherapy of MET-expressing malignant mesothelioma

Thivyan ThayaparanKing's College London, Division of Cancer Studies, Guy's Hospital, Great Maze Pond, LondonSE1 9RT, UK
,
Roseanna M. PetrovicKing's College London, Division of Cancer Studies, Guy's Hospital, Great Maze Pond, LondonSE1 9RT, UKORCID Iconhttp://orcid.org/0000-0002-5876-720X
ORCID Icon,
Daniela Y. AchkovaKing's College London, Division of Cancer Studies, Guy's Hospital, Great Maze Pond, LondonSE1 9RT, UK
,
Tomasz ZabinskiKing's College London, Division of Cancer Studies, Guy's Hospital, Great Maze Pond, LondonSE1 9RT, UK
,
David M. DaviesKing's College London, Division of Cancer Studies, Guy's Hospital, Great Maze Pond, LondonSE1 9RT, UK
,
Astero KlampatsaKing's College London, Division of Cancer Studies, Guy's Hospital, Great Maze Pond, LondonSE1 9RT, UK;Pulmonary, Allergy & Critical Care Division, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
,
Ana C. Parente-PereiraKing's College London, Division of Cancer Studies, Guy's Hospital, Great Maze Pond, LondonSE1 9RT, UK
,
Lynsey M. WhildingKing's College London, Division of Cancer Studies, Guy's Hospital, Great Maze Pond, LondonSE1 9RT, UK
,
Sjoukje JC van der StegenThe Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, New York, USA
,
Natalie WoodmanKing's College London, Division of Cancer Studies, Guy's Hospital, Great Maze Pond, LondonSE1 9RT, UK
,
Michael SheaffDepartment of Histopathology, Barts Health NHS Trust, The Royal London Hospital, LondonE1 2ES, UK
,
Jennifer R. CochranDepartment of Bioengineering and Chemical Engineering, Stanford Cancer Institute, 443 Via Ortega, Room 356, Stanford, CA, USA
,
James F. SpicerKing's College London, Division of Cancer Studies, Guy's Hospital, Great Maze Pond, LondonSE1 9RT, UK;Department of Medical Oncology, Guy's and St Thomas' NHS Foundation Trust, London, UK
&
John MaherKing's College London, Division of Cancer Studies, Guy's Hospital, Great Maze Pond, LondonSE1 9RT, UK;Department of Clinical Immunology and Allergy, King's College Hospital NHS Foundation Trust, Denmark Hill, LondonSE5 9RS, UK;Department of Immunology, Eastbourne Hospital, Kings Drive, Eastbourne, East Sussex, BN21 2UD, UKCorrespondence[email protected]
 show all
Article: e1363137 | Received 10 Apr 2017, Accepted 31 Jul 2017, Published online: 25 Aug 2017

Citations (40)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (5)

John Maher. (2023) Chimeric Antigen Receptor (CAR) T-Cell Therapy for Patients with Lung Cancer: Current Perspectives. OncoTargets and Therapy 16, pages 515-532.
Read now
Haiyan Ma, Wenwen Wei, Dandan Liang, Xing Xu, Dong Yang, Qiong Wang, Yun Wang, Quan Wei, Bin Sun & Xudong Zhao. (2023) HGF-Based CAR-T Cells Target Hepatocellular Carcinoma Cells That Express High Levels of c-Met. Immunological Investigations 52:6, pages 735-748.
Read now
Emily Harrold, Lynda Corrigan, Simon Barry & Maeve Lowery. (2022) Targeting MET amplification in Gastro-oesophageal (GO) malignancies and overcoming MET inhibitor resistance: challenges and opportunities. Expert Review of Gastroenterology & Hepatology 16:7, pages 601-624.
Read now
Cong Chen, Yan-Mei Gu, Fan Zhang, Zheng-Chao Zhang, Ya-Ting Zhang, Yi-Di He, Ling Wang, Ning Zhou, Fu-Tian Tang, Hong-Jian Liu & Yu-Min Li. (2021) Construction of PD1/CD28 chimeric-switch receptor enhances anti-tumor ability of c-Met CAR-T in gastric cancer. OncoImmunology 10:1.
Read now
Haidar El Darsa, Rola El Sayed & Omar Abdel-Rahman. (2020) MET Inhibitors for the Treatment of Gastric Cancer: What’s Their Potential?. Journal of Experimental Pharmacology 12, pages 349-361.
Read now

Articles from other publishers (35)

Sara Abdalrazzaq M. Noraldeen, Irodakhon Rasulova, Repudi Lalitha, Farah Hussin, Hashem O. Alsaab, Ahmed Hussien Alawadi, Ali Alsaalamy, Nidhal Hassan Sayyid, Adnan Taan Alkhafaji, Yasser Fakri Mustafa & Sepideh Karkon Shayan. (2023) Involving stemness factors to improve CAR T-cell-based cancer immunotherapy. Medical Oncology 40:11.
Crossref
Haihong Zhao, Lina Wu, Jiemin Dai, Ke Sun, Zhenguo Zi, Junhua Guan & Liwen Zhang. (2023) Ligand-based adoptive T cell targeting CA125 in ovarian cancer. Journal of Translational Medicine 21:1.
Crossref
Vardges Tserunyan & Stacey D. Finley. (2023) A systems and computational biology perspective on advancing CAR therapy. Seminars in Cancer Biology 94, pages 34-49.
Crossref
Farhoodeh Ghaedrahmati, Nafiseh Esmaeil & Maryam Abbaspour. (2022) Targeting immune checkpoints: how to use natural killer cells for fighting against solid tumors. Cancer Communications 43:2, pages 177-213.
Crossref
Sibi Raj, Kavindra Kumar Kesari, Arun Kumar, Brijesh Rathi, Ashok Sharma, Piyush Kumar Gupta, Saurabh Kumar Jha, Niraj Kumar Jha, Petr Slama, Shubhadeep Roychoudhury & Dhruv Kumar. (2022) Molecular mechanism(s) of regulation(s) of c-MET/HGF signaling in head and neck cancer. Molecular Cancer 21:1.
Crossref
Lu Wang, Xinyi Chen, Lu Zhang, Boning Niu, Long Li, Yinan Sun & Xianglin Yuan. (2022) CAR cell design strategies in solid tumors. International Immunopharmacology 113, pages 109345.
Crossref
Cristina Chiriaco, Chiara Donini, Marco Cortese, Stefano Ughetto, Chiara Modica, Ilaria Martinelli, Alessia Proment, Letizia Vitali, Lara Fontani, Monica Casucci, Paolo Maria Comoglio, Silvia Giordano, Dario Sangiolo, Valeria Leuci & Elisa Vigna. (2022) Efficacy of CAR-T immunotherapy in MET overexpressing tumors not eligible for anti-MET targeted therapy. Journal of Experimental & Clinical Cancer Research 41:1.
Crossref
Dean A. Fennell, Sean Dulloo & James Harber. (2022) Immunotherapy approaches for malignant pleural mesothelioma. Nature Reviews Clinical Oncology 19:9, pages 573-584.
Crossref
Denis Kuznetsov, Sergey Dezhurov, Dmitri Krylsky & Valery Neschisliaev. (2022) Fluorescent nanosensors for molecular visualization of the c-Met tumor marker. Nano-Structures & Nano-Objects 31, pages 100890.
Crossref
Zhiquan Hao, Siqiao Wang, Zixuan Zheng, Jiehan Li, Wanting Fu, Donglin Han, Yinrou Huang, Qing Lin, Shuyuan Xian, Penghui Yan, Man Li, Ruoyi Lin, Tong Meng, Jie Zhang & Zongqiang Huang. (2022) Prognostic Bone Metastasis-Associated Immune-Related Genes Regulated by Transcription Factors in Mesothelioma. BioMed Research International 2022, pages 1-26.
Crossref
Laura Castelletti, Dannel Yeo, Nico van Zandwijk & John E. J. Rasko. (2021) Anti-Mesothelin CAR T cell therapy for malignant mesothelioma. Biomarker Research 9:1.
Crossref
Gang Cheng, Hui Dong, Chen Yang, Yang Liu, Yi Wu, Lifen Zhu, Xiangmin Tong & Shibing Wang. (2021) A review on the advances and challenges of immunotherapy for head and neck cancer. Cancer Cell International 21:1.
Crossref
Javad Masoumi, Abdollah Jafarzadeh, Jalal Abdolalizadeh, Haroon Khan, Jeandet Philippe, Hamed Mirzaei & Hamid Reza Mirzaei. (2021) Cancer stem cell-targeted chimeric antigen receptor (CAR)-T cell therapy: Challenges and prospects. Acta Pharmaceutica Sinica B 11:7, pages 1721-1739.
Crossref
S. V. Timofeeva, A. O. Sitkovskaya, I. A. Novikova, M. A. Ezhova, E. P. Lysenko & O. I. Kit. (2021) Recent achievements in CAR-T cell immunotherapy for glioblastoma treatment. Medical Immunology (Russia) 23:3, pages 483-496.
Crossref
Tahereh Soltantoyeh, Behnia Akbari, Amirali Karimi, Ghanbar Mahmoodi Chalbatani, Navid Ghahri-Saremi, Jamshid Hadjati, Michael R. Hamblin & Hamid Reza Mirzaei. (2021) Chimeric Antigen Receptor (CAR) T Cell Therapy for Metastatic Melanoma: Challenges and Road Ahead. Cells 10:6, pages 1450.
Crossref
Rita Terenziani, Silvia Zoppi, Claudia Fumarola, Roberta Alfieri & Mara Bonelli. (2021) Immunotherapeutic Approaches in Malignant Pleural Mesothelioma. Cancers 13:11, pages 2793.
Crossref
Maryam Akhoundi, Mahsa Mohammadi, Seyedeh Saeideh Sahraei, Mohsen Sheykhhasan & Nashmin Fayazi. (2021) CAR T cell therapy as a promising approach in cancer immunotherapy: challenges and opportunities. Cellular Oncology 44:3, pages 495-523.
Crossref
Steven G. Gray. (2021) Emerging avenues in immunotherapy for the management of malignant pleural mesothelioma. BMC Pulmonary Medicine 21:1.
Crossref
Wei Jiang, Tao Li, Jiaojiao Guo, Jingjing Wang, Lizhou Jia, Xiao shi, Tingting Yang, Ruonan Jiao, Xin Wei, Zhenqing Feng, Qi Tang & Guozhong Ji. (2021) Bispecific c-Met/PD-L1 CAR-T Cells Have Enhanced Therapeutic Effects on Hepatocellular Carcinoma. Frontiers in Oncology 11.
Crossref
Karen L Reckamp, Jasmine A McQuerry, Isa Mambetsariev, Rebecca Pharaon, Susan E Yost, Jeremy Fricke, Tamara Mirzapoiazova, Raju K Pillai, Leonidas Arvanitis, Ziad Khan, Marwan Fakih, Yuan Yuan, Marianna Koczywas, Erminia Massarelli, Prakash Kulkarni, Sumanta K Pal, Martin Sattler, Andrea Bild & Ravi Salgia. (2021) Co-stimulatory and co-inhibitory immune markers in solid tumors with MET alterations . Future Science OA 7:2.
Crossref
Hang-Ping Yao, Xiang-Min Tong & Ming-Hai Wang. (2021) Oncogenic mechanism-based pharmaceutical validation of therapeutics targeting MET receptor tyrosine kinase. Therapeutic Advances in Medical Oncology 13, pages 175883592110069.
Crossref
Danijela Štrbac, Katja Goričar, Viljem Kovač & Vita Dolžan. 2020. Mesothelioma. Mesothelioma.
Pierre Antoine & John Maher. (2020) Developing a safe and effective CAR T-cell immunotherapy for breast cancer: progress and pitfalls. Breast Cancer Management 9:3.
Crossref
David Michael Abbott, Chandra Bortolotto, Silvia Benvenuti, Andrea Lancia, Andrea Riccardo Filippi & Giulia Maria Stella. (2020) Malignant Pleural Mesothelioma: Genetic and Microenviromental Heterogeneity as an Unexpected Reading Frame and Therapeutic Challenge. Cancers 12:5, pages 1186.
Crossref
Xing Huang, Enliang Li, Hang Shen, Xun Wang, Tianyu Tang, Xiaozhen Zhang, Jian Xu, Zengwei Tang, Chengxiang Guo, Xueli Bai & Tingbo Liang. (2020) Targeting the HGF/MET Axis in Cancer Therapy: Challenges in Resistance and Opportunities for Improvement. Frontiers in Cell and Developmental Biology 8.
Crossref
Jonas P. Koch, Daniel M. Aebersold, Yitzhak Zimmer & Michaela Medová. (2020) MET targeting: time for a rematch. Oncogene 39:14, pages 2845-2862.
Crossref
Jacob S. Appelbaum, Navin Pinto & Rimas J. Orentas. 2020. Chimeric Antigen Receptor T-Cell Therapies for Cancer. Chimeric Antigen Receptor T-Cell Therapies for Cancer 137 163 .
Yan Liu, Yehui Zhou, Kuo-Hsiang Huang, Ying Li, Xujie Fang, Li An, Feifei Wang, Qingfei Chen, Yunchao Zhang, Aihua Shi, Shuang Yu & Jingzhong Zhang. (2019) EGFR-specific CAR-T cells trigger cell lysis in EGFR-positive TNBC. Aging 11:23, pages 11054-11072.
Crossref
Yuan Mao, Weifei Fan, Hao Hu, Louqian Zhang, Jerod Michel, Yaqin Wu, Jun Wang, Lizhou Jia, Xiaojun Tang, Li Xu, Yan Chen, Jin Zhu, Zhenqing Feng, Lin Xu, Rong Yin & Qi Tang. (2019) MAGE-A1 in lung adenocarcinoma as a promising target of chimeric antigen receptor T cells. Journal of Hematology & Oncology 12:1.
Crossref
Marina Martinez & Edmund Kyung Moon. (2019) CAR T Cells for Solid Tumors: New Strategies for Finding, Infiltrating, and Surviving in the Tumor Microenvironment. Frontiers in Immunology 10.
Crossref
Vasyl Eisenberg, Shiran Hoogi, Astar Shamul, Tilda Barliya & Cyrille J. Cohen. (2019) T-cells “à la CAR-T(e)” – Genetically engineering T-cell response against cancer. Advanced Drug Delivery Reviews 141, pages 23-40.
Crossref
Federica Papaccio, Carminia Della Corte, Giuseppe Viscardi, Raimondo Di Liello, Giovanna Esposito, Francesca Sparano, Fortunato Ciardiello & Floriana Morgillo. (2018) HGF/MET and the Immune System: Relevance for Cancer Immunotherapy. International Journal of Molecular Sciences 19:11, pages 3595.
Crossref
Alfredo Tartarone, Rosa Lerose & Michele Aieta. (2018) Is there a role for immunotherapy in malignant pleural mesothelioma?. Medical Oncology 35:7.
Crossref
Louai Labanieh, Robbie G. Majzner & Crystal L. Mackall. (2018) Programming CAR-T cells to kill cancer. Nature Biomedical Engineering 2:6, pages 377-391.
Crossref
Cong Chen, Yan-mei Gu, Zheng-chao Zhang, Ya-ting Zhang, Yi-di He, Fu-tian Tang, Hong-jian Liu & Yu-min Li. (2020) Construction of PD1/CD28 Fusion Receptor Enhances Anti-Tumor Ability of c-Met CAR-T in Gastric Cancer. SSRN Electronic Journal.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.